Morgillo F - Search Results

1

Morgillo F, Lee HY. Morgillo F, et al. Expert Opin Investig Drugs. 2006 Jun;15(6):709-19. doi: 10.1517/13543784.15.6.709. Expert Opin Investig Drugs. 2006. PMID: 16732721 Review.

2

Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer.

Han JY, Oh SH, Morgillo F, Myers JN, Kim E, Hong WK, Lee HY. Han JY, et al. Among authors: morgillo f. J Natl Cancer Inst. 2005 Sep 7;97(17):1272-86. doi: 10.1093/jnci/dji251. J Natl Cancer Inst. 2005. PMID: 16145048

3

Resistance to epidermal growth factor receptor-targeted therapy.

Morgillo F, Lee HY. Morgillo F, et al. Drug Resist Updat. 2005 Oct;8(5):298-310. doi: 10.1016/j.drup.2005.08.004. Epub 2005 Sep 19. Drug Resist Updat. 2005. PMID: 16172017 Review.

4

Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.

Morgillo F, Woo JK, Kim ES, Hong WK, Lee HY. Morgillo F, et al. Cancer Res. 2006 Oct 15;66(20):10100-11. doi: 10.1158/0008-5472.CAN-06-1684. Cancer Res. 2006. PMID: 17047074

5

Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.

Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK, Lee HY. Morgillo F, et al. Clin Cancer Res. 2007 May 1;13(9):2795-803. doi: 10.1158/1078-0432.CCR-06-2077. Clin Cancer Res. 2007. PMID: 17473213

6

Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells.

Cascone T, Morelli MP, Morgillo F, Kim WY, Rodolico G, Pepe S, Tortora G, Berrino L, Lee HY, Heymach JV, Ciardiello F. Cascone T, et al. Among authors: morgillo f. J Cell Physiol. 2008 Sep;216(3):698-707. doi: 10.1002/jcp.21444. J Cell Physiol. 2008. PMID: 18381602

7

Metformin in lung cancer: rationale for a combination therapy.

Morgillo F, Sasso FC, Della Corte CM, Festino L, Manzo A, Martinelli E, Troiani T, Capuano A, Ciardiello F. Morgillo F, et al. Expert Opin Investig Drugs. 2013 Nov;22(11):1401-9. doi: 10.1517/13543784.2013.828691. Epub 2013 Aug 12. Expert Opin Investig Drugs. 2013. PMID: 23937224 Review.

8

Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer.

Fasano M, Della Corte CM, Califano R, Capuano A, Troiani T, Martinelli E, Ciardiello F, Morgillo F. Fasano M, et al. Among authors: morgillo f. Expert Opin Investig Drugs. 2014 Jun;23(6):809-21. doi: 10.1517/13543784.2014.902934. Epub 2014 Mar 28. Expert Opin Investig Drugs. 2014. PMID: 24673358 Review.

9

Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer.

Troiani T, Martinelli E, Orditura M, De Vita F, Ciardiello F, Morgillo F. Troiani T, et al. Among authors: morgillo f. Expert Opin Investig Drugs. 2012 Jul;21(7):949-59. doi: 10.1517/13543784.2012.689287. Epub 2012 May 22. Expert Opin Investig Drugs. 2012. PMID: 22612461 Review.

10

Emerging VEGF-receptor inhibitors for colorectal cancer.

Martinelli E, Troiani T, Morgillo F, Orditura M, De Vita F, Belli G, Ciardiello F. Martinelli E, et al. Among authors: morgillo f. Expert Opin Emerg Drugs. 2013 Mar;18(1):25-37. doi: 10.1517/14728214.2013.749856. Epub 2012 Dec 6. Expert Opin Emerg Drugs. 2013. PMID: 23216053 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

168 results

Search Page